GPT and metabolic dysfunction-associated steatotic liver disease: A 2024 review further confirmed that GLP-1RA therapy reduces liver fat and NASH, demonstrating decreases in body weight, serum biomarkers such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and MRI-measured liver fat content in patients with NAFLD [18].